NASDAQ:CELG - Celgene Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$90.37 +0.22 (+0.24 %)
(As of 08/19/2018 07:38 AM ET)
Previous Close$90.37
Today's Range$89.24 - $90.97
52-Week Range$74.13 - $147.17
Volume4.12 million shs
Average Volume7.05 million shs
Market Capitalization$64.15 billion
P/E Ratio13.21
Dividend YieldN/A
Celgene logoCelgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA, a small molecule inhibitor of the isocitrate dehydrogenase 2 to treat acute myeloid leukemia (AML); VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; and THALOMID to treat patients with MM and erythema nodosum leprosum. Its clinical stage products comprise OTEZLA for use in treating various immune-inflammatory diseases; luspatercept for the treatment of patients with beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; CC-92480 to treat multiple myeloma; and durvalumab, an anti-PD-L1 antibody for multiple hematological cancers. The company has agreement with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; Vividion Therapeutics, Inc.; Jounce Therapeutics, Inc.; Prothena Corporation plc; Zymeworks Inc.; and Evotec AG, as well as strategic collaboration with Skyhawk Therapeutics, Inc. The company was founded in 1980 and is headquartered in Summit, New Jersey.

Receive CELG News and Ratings via Email

Sign-up to receive the latest news and ratings for CELG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity Ratio5.76
Current Ratio1.52
Quick Ratio1.40


Trailing P/E Ratio13.21
Forward P/E Ratio11.83
P/E Growth0.57

Sales & Book Value

Annual Sales$13.00 billion
Price / Sales4.89
Cash Flow$7.5497 per share
Price / Cash11.97
Book Value$8.79 per share
Price / Book10.28


EPS (Most Recent Fiscal Year)$6.84
Net Income$2.94 billion
Net Margins19.81%
Return on Equity87.28%
Return on Assets17.05%


Outstanding Shares703,360,000
Market Cap$64.15 billion

Celgene (NASDAQ:CELG) Frequently Asked Questions

What is Celgene's stock symbol?

Celgene trades on the NASDAQ under the ticker symbol "CELG."

When did Celgene's stock split? How did Celgene's stock split work?

Celgene shares split before market open on Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly issued shares were distributed to shareholders after the closing bell on Wednesday, June 25th 2014. An investor that had 100 shares of Celgene stock prior to the split would have 200 shares after the split.

How will Celgene's stock buyback program work?

Celgene announced that its Board of Directors has approved a stock repurchase plan on Thursday, May 24th 2018, which allows the company to repurchase $3,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to repurchase up to 5.4% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company's leadership believes its shares are undervalued.

How were Celgene's earnings last quarter?

Celgene Co. (NASDAQ:CELG) issued its quarterly earnings results on Thursday, July, 26th. The biopharmaceutical company reported $2.16 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $2.11 by $0.05. The biopharmaceutical company had revenue of $3.81 billion for the quarter, compared to analysts' expectations of $3.70 billion. Celgene had a return on equity of 87.28% and a net margin of 19.81%. Celgene's revenue for the quarter was up 16.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.82 EPS. View Celgene's Earnings History.

When is Celgene's next earnings date?

Celgene is scheduled to release their next quarterly earnings announcement on Thursday, October, 25th 2018. View Earnings Estimates for Celgene.

What guidance has Celgene issued on next quarter's earnings?

Celgene updated its FY18 earnings guidance on Thursday, July, 26th. The company provided earnings per share guidance of $8.70-8.75 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $8.53. The company issued revenue guidance of $15 billion, compared to the consensus revenue estimate of $14.91 billion.

What price target have analysts set for CELG?

33 brokers have issued 1-year target prices for Celgene's shares. Their predictions range from $85.00 to $166.00. On average, they anticipate Celgene's share price to reach $122.8077 in the next twelve months. This suggests a possible upside of 35.9% from the stock's current price. View Analyst Price Targets for Celgene.

What is the consensus analysts' recommendation for Celgene?

33 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celgene in the last year. There are currently 1 sell rating, 12 hold ratings and 20 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Celgene.

What are Wall Street analysts saying about Celgene stock?

Here are some recent quotes from research analysts about Celgene stock:
  • 1. According to Zacks Investment Research, "Celgene’s second-quarter results were impressive as the company beat on both sales and earnings. Revlimid sales were impressive yet again, along with Pomalyst and Otezla. The increase in annual guidance on the back of Revlimid sales should boost investors’ sentiment, given the recent spate of pipeline setbacks. The company is focussed on the next cycle of innovation with five late stage candidates. In a bid to revive its pipeline, Celgene acquired Juno Therapeutics and added JCAR017 to its lymphoma pipeline. Celgene expects to submit its NDA for fedratinib in myelofibrosis by the end of 2018. The company remains on track with submissions for ozanimod, both in the United States and EU, for relapsing multiple sclerosis in the first quarter of 2019. Luspatercept looks promising as well with positive data from two late-stage trials. However, shares have underperformed the industry in the year so far." (8/1/2018)
  • 2. Mizuho analysts commented, "We updated our model post the 2Q18 earnings call. Here are the key changes we made: ===Upward Revisions=== 1. bb2121. Added bb2121 to pipeline section of the model ($1Bn in risk- adjusted peak sales to CELG vs consensus of $900MM) 2. Luspatercept. Increased POS from 67% to 90% on the back of the recent positive Ph 3 results. (peak risk-adj sales now of $1Bn, ex-royalty to XLRN …. consensus at $850MM) ===Downward Revisions=== 3. Ozanimod MS. Trimmed peak risked adjusted sales from $1.3Bn to $1.1Bn. In total, across all 3 indications (MS, UC, CD), we carry $2.8Bn (vs consensus of $2.5Bn)." (7/31/2018)
  • 3. Cowen Inc analysts commented, "We will be hosting a conference call with neurologist to discuss and TD-9855. Theravance is evaluating 1/2 trial in patients with . Results are expected to be available this month." (7/10/2018)
  • 4. Canaccord Genuity analysts commented, "We expect median Progression Free Survival (PFS) > 10 months for the initial bb2121 dose escalation cohort previously reported at ASH 2017, based on 71% progression free at 9 months. Importantly, we believe PFS data could easily exceed our estimate and the 8.8 months PFS seen for pomalidomide + daratumumab + dexamethasone in Phase 1b. Duration of follow-up key for new n=21 patient cohort Investors should carefully consider the median follow-up time for the new n=21 patient bb2121 cohort with no BCMA expression cutoff, since Complete Responses improve over time. We will consider the initial bb2121 data presented at AACR in 2016, where a 78% ORR and 22% CR rate was seen. Importantly, we expect a very rapid Overall Response Rate, as seen for initial bb2121 data." (5/30/2018)

Who are some of Celgene's key competitors?

Who are Celgene's key executives?

Celgene's management team includes the folowing people:
  • Mr. Mark J. Alles, Chairman & CEO (Age 59)
  • Mr. Peter N. Kellogg, Exec. VP, CFO & Chief Accounting Officer (Age 62)
  • Dr. S. J. Rupert Vessey, EVP, Pres of Research & Early Devel. (Age 53)
  • Mr. Patrick E. Flanigan III, Corp. VP of Investor Relations
  • Mr. Gerald F. Masoudi, Exec. VP, Gen. Counsel & Corp. Sec. (Age 50)

Has Celgene been receiving favorable news coverage?

Media stories about CELG stock have been trending somewhat positive on Sunday, Accern Sentiment reports. Accern identifies negative and positive media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Celgene earned a news impact score of 0.12 on Accern's scale. They also assigned headlines about the biopharmaceutical company an impact score of 47.56 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. View Recent Headlines for Celgene.

Who are Celgene's major shareholders?

Celgene's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Edgewood Management LLC (1.98%), Janus Henderson Group PLC (1.29%), FMR LLC (1.16%), Bank of New York Mellon Corp (0.93%), Jennison Associates LLC (0.78%) and Renaissance Technologies LLC (0.59%). Company insiders that own Celgene stock include Corp /De/ Celgene, Ernest Mario, Gilla Kaplan, James J Loughlin, John H Weiland, Mark J Alles, Michael A Friedman, Michael D Casey, Richard W Barker, Robert J Hugin, Rupert Vessey and Terrie Curran. View Institutional Ownership Trends for Celgene.

Which institutional investors are selling Celgene stock?

CELG stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Voya Investment Management LLC, Canada Pension Plan Investment Board, OppenheimerFunds Inc., Natixis, Massachusetts Financial Services Co. MA, Standard Life Aberdeen plc and Morgan Stanley. Company insiders that have sold Celgene company stock in the last year include Ernest Mario, Gilla Kaplan, James J Loughlin, Michael D Casey and Terrie Curran. View Insider Buying and Selling for Celgene.

Which institutional investors are buying Celgene stock?

CELG stock was acquired by a variety of institutional investors in the last quarter, including Edgewood Management LLC, Renaissance Technologies LLC, FMR LLC, Swedbank, Chevy Chase Trust Holdings Inc., LGT Capital Partners LTD., Gateway Investment Advisers LLC and ADAMCAPITAL Gestao de Recursos Ltda.. Company insiders that have bought Celgene stock in the last two years include Corp /De/ Celgene, John H Weiland and Mark J Alles. View Insider Buying and Selling for Celgene.

How do I buy shares of Celgene?

Shares of CELG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Celgene's stock price today?

One share of CELG stock can currently be purchased for approximately $90.37.

How big of a company is Celgene?

Celgene has a market capitalization of $64.15 billion and generates $13.00 billion in revenue each year. The biopharmaceutical company earns $2.94 billion in net income (profit) each year or $6.84 on an earnings per share basis. Celgene employs 7,467 workers across the globe.

How can I contact Celgene?

Celgene's mailing address is 86 MORRIS AVENUE, SUMMIT NJ, 07901. The biopharmaceutical company can be reached via phone at 908-673-9000 or via email at [email protected]

MarketBeat Community Rating for Celgene (NASDAQ CELG)

Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  1,821 (Vote Outperform)
Underperform Votes:  622 (Vote Underperform)
Total Votes:  2,443
MarketBeat's community ratings are surveys of what our community members think about Celgene and other stocks. Vote "Outperform" if you believe CELG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CELG will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/19/2018 by Staff

Featured Article: Earnings Per Share

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.